Help
Options
Didn't know it?
click below
click below
Knew it?
click below
click below
Don't Know
Remaining cards (0)
Know
retry
shuffle
restart
0:00
Embed Code - If you would like this activity on your web page, copy the script below and paste it into your web page.
Normal Size Small Size show me how
Normal Size Small Size show me how
oncology
drugs
| Question | Answer |
|---|---|
| which drug is a reversible inhibitor of EGFR? | Gefitinib |
| interstitial lung disease is seen with what drugs? | Gefitinib and osemertinib, pralsetinib , amivantamab-vmjw |
| this drug competes with ATP binding to cytoplasmic tyrosine kinase domain and also causes cell cycle arrest at the G0/G1 boundary? | Gefitinib |
| What targets does Lapatinib hit | HER2 EGFR |
| what is a BBW seen with Lapatinib | hepatotoxicity |
| What drugs are the irreversible inhibitors of EGFR | Lapatinib Afatinib Osimertinib |
| what targets does Neratinib and Afatinib hit? | HER2, EGFR, HER4 |
| what is the drug interaction of using neratinib and BTK inhibitors | PPIs |
| Is omeprazole a drug interaction for the use of neratinib? | yes |
| True of false: Tucatinib is highly selective for HER2 | true |
| side effect of tucatinib | diarrhea and hepatotoxicity |
| what is the purpose of using tucatinib and trastuzumab together? | improves outcomes probably due to targeting intracellular and extracellular domains of HER2. Together have increased anti-tumor activity compared to either drug alone |
| This drug is an irreversible EGFR antagonist for mutant/variant forms of EGFR. Including T790M, L858R, and exon 19 deletion | osimertinib |
| this drug has lung, GI, and dermatologic toxicity? | osimertinib |
| what do you need to evaluate for before using Cetuximab? | KRAS mutation |
| osimertinib targets what | EGFR |
| tucatinib targets HER2 or EGFR | HER2 |
| BBW of cetuximab | infusion reactions and cardiopulmonary arrest |
| This drug targets EGFR and what BBW does it have | dermatologic reactions |
| this drug is a human IgG2 kappa monoclonal antibody | panitumumab |
| BBW of trastuzumab | cardiomyopathy |
| what drug has a DI with warfarin, therefore they monitor prothrombin time ratio or INR | trastuzumab |
| what drug can you not substitute for trastuzumab | ado-trastuazumab emtansine |
| what drug is cardiotoxic and decreases LVEF | ado-trastuzumab emtansine |
| what drug is used with trastuzumab as they target different regions on HER2 receptor | pertuzumab |
| what drug has left ventricular dysfunction and embryo-fetal toxicity as a BBW | pertuzumab |
| what are the targets that crizotinib hits | ALK, ROS1, MET |
| what is the common side effect seen with crizotinib | vision disturbances |
| which drugs are the second-generation ALK inhibitors that have better BBB penetration | Brigatinib, Ensartinib, Alectinib |
| with what drug do you see the side effect of hyperlipidemia? | ensartinib |
| when using brigatinib, what do you have to do to decrease risk of pulmonary toxicites? | dose escalation |
| this drug is a third generation ALK inhibitor and ROS1 inhibitor | lorlatinib |
| what drug is used in combo with cytotoxic chemotherapy for the treatmetns of FLT3-positive AML | midostaurin |
| this drug has an active metabolite AC886? | quizartinib |
| what are the 2 variants that midostaurin inhibits | ITD & TKD |
| is midostaurin or quizartinib more potent for the ITD varian | quizartinib |
| what are the CI when using quizartinib | severe hypokalemia, severe hypomagnesemia, long QT syndrome |
| what is a serious side effect of using larotrectinib | neurotoxicity & hepatotoxicity |
| larotrectinib inhibits what? | TRKA, TRKB, TRKC |
| which drug is the second generation inhibitor of TRKA, TRKB, and TRKC kinases and ROS1 | repotrectinib |
| what are the serious side effects of using repotrectinib | neurotoxicity, hepatotoxicity, pneumonia |
| this drug inhibits TRKA, TRKB, TRKC, ROS1, AND ALK kinases, what is it | entrectinib |
| this receptor is involved in the development of different organ systems including hematopoiesis, CNS, AND GIT | RET |
| this drug requires close monitoring ever 2 weeks and has an adverse effect of impaired wound healing? | selpercatinib |
| what does selpercatinib inhibit | wild-type and mutated RET isoforms, VEGFR & FGFRs |
| are the RET inhibitors metabolized by CYP3A4 | yes |
| this RET inhibitor can cause severe interstitial lung disease/pneumonitis & hypertension | pralsetinib |
| this is a tyrosine kinase receptor that's ligand is hepatocyte growth factor | MET |
| What drugs are RET inhibitors | selpercatinib & praslsetinib |
| what drugs are MET inhibitors | Capmatinib, tepotinib, amivatamab-vmjw |
| this drug has an AE of tumor lysis syndrome | selpercatinib |
| this is a SELECTIVE MET kinase inhibitor | capmatinib |
| these drugs can cause peripheral edema | MET inhibitors Capmatinib & Tepotinib |
| what are the AE of tepotinib | peripheral edema, fatigue, dyspepsia, and musculo-skeletal pain |
| capmatinib and tepotinib are what | met INHIBITORS |
| what drug is new and targets both MET & EGFR at the same time | amivantamab-vmjw |
| this drug has affinity for EGFR exon 19 deletions, exon 21 L858R substitutions, and exam 20 insertions? | amivantamab- vmjw |
| with what drug do you have to be aware of DVT, clots, pulmonary embolism | amivantamab-vmjw |
| what drugs are the BTK inhibitors | acalabrutinib and Zanubrutinib |
| Acalabrutinib and Zanubrutinib are what | second generation BTK inhibitors: more selective |
| are the BTK inhibitors reversible or irreversible | irreversible |
| what are the DI of using BTK inhibitors | PPIs, antacids, cyp3A4 inhibitor |
| serious effect of using acalabrutinib or zanubrutinib | hemorrhaging |
| which drug may have a better AE profile. acalabrutinib or zanubrutinib | acalabrutinib |
| which is the fusion protein created by the abnormal philadelphia chromosome, which characterizes chronic myeloid leukemia | BCR-ABL |
| activation of this growth hormone may contribute to cancer pathology by causing angiogenesis & metastasis | PDGFR |
| muatations to this gene are associated with various leukemias and GI stromal tumors | KIT |
| what are the 3 different pathways that EGFR goes through | RAS-MAP , PI3K - AKT, JAK-STAT |
| Which signal transduction antagonists hits all 3 signals pathways | Imatinib |
| MOA of imatinib | Targets ABL'S ATP binding site when activation loop is closed; stabilizes BCR-ABL in inactive conformation and hold that kinase in an inactive form until drug falls off receptor. it is reversible |
| what is the clinical toxicity seen with the use of imatinib | neutropenia & thrombocytopenia |
| Imatinib targts what | BCR-ABL, PDGFR, KIT |
| with what drug do you see elevated liver enzymes | imatinib |
| out of Dasatinib and Nilotinib, which one has the highest affinity for wild type BCR-ABL | nilotinib |
| MOA of Bosutinib | will inhibit most imatinib-resistance BCR-ABL genetic variant except T315I mutant |
| what is the difference between Bosutinib and ponatinib | Bosutinib inhibits most imatinib-resistance BCR- ABL genetics variant except T315I but pontinib inhibits T315I |
| MOA of asciminib | asciminib bind to the myristate pocket and that ABL can't be active, preventing BCR-ABL kinase activity; a STAMP drug |
| what drugs are the BRAF inhibitors | Dabrafenib and encorafenib |
| what are the most common mutations seen in the activation loop of BRAF | must mutations at codon 600 V600E and V699K |
| what are the AE seen with both BRAF inhibitors | QT prolongation, severe dermatologic reactions, and photosensitivity |
| what drugs are the MEK inhibitors | Tremetinib and Binimetinib |
| MOA of both tremetinib and binimetinib | inhibits MEK1 & 2 as well as BRAF V600E |
| secondary resistance is seen with the MEK inhibitors, but why | -activation of alternative signaling pathways -mutations in the allosteric binding socket and activation loop of MEK1 -occurs with 6-7 months of first use |
| what drugs are the CDK inhibitors | palbociclib ribociclib abemaciclib |
| MOA of the CDK inhibitors | selectively inhibits CDK4/6 |
| what is a good counseling point of using a CDK inhibitor | take with food |
| with what CDK inhibitor do you avoid the use of other QT interval elongating drugs | ribociclib |
Created by:
KaHerre12